drugset / Trial / NCT01357356

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia

NCT01357356

Phase 2/3 Completed 750 enrolled Serenity Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia for a total duration of 14 weeks.

Timeline

Start
2011-05
Primary completion
2012-10
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Desmopressin Peptide 750 ng Intranasal
Subject Desmopressin Peptide 1000 ng Intranasal
Subject Desmopressin Peptide 1500 ng Intranasal

Indications